Jefferies Upgrades Emerson (EMR) to Buy

Jefferies analyst Stephen Volkmann upgraded Emerson (NYSE: EMR) from Hold to Buy with a price target of $175.00 (from $160.00).

The analyst comments: "We assume coverage of EMR and upgrade to BUY. Strong orders momentum across core growth verticals should support an acceleration in earnings growth from LSD in 1H to LDD exiting FY26 and into FY27. In addition, EMR has delivered 800 bps of margin improvement through operation and portfolio actions over the last decade which we believe will support higher valuation multiples. Our $175 PT reflects 19x 2027E EV/EBITDA, in line with premium industrial peers."

For an analyst ratings summary and ratings history on Emerson click here. For more ratings news on Emerson click here.

Shares of Emerson closed at $123.30 yesterday.

You May Also Be Interested In

• Barclays Upgrades Visteon (VC) to Overweight
• Citizens Starts NRC Health (NRC) at Market Outperform
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight